A combination of Novartis’ 'next generation' CAR-T drug CTL119 with Janssen and AbbVie's Imbruvica has cleared all signs of chronic lymphocytic leukaemia from eight out of nine patients in
Sandoz has signed a potential $293 million agreement to develop and market Durect’s Posimir, an extended-release, locally-acting, non-opioid painkiller in the US.
